| Revenue growth | Q2 +46.8% YoY; H1 +44.7% YoY (standalone) |
|---|---|
| Margins | Q2 EBITDA 22.17%, down 265bps QoQ; H1 23.40% |
| Demand visibility | CDMO: 23 customers, 59 projects, 39 commercial |
Growth
Q2 revenue +46.8% YoY, +14.6% QoQ. H1 revenue +44.7%, PAT +92.6% to INR 1,371Mn.
Outlook
Targets 15-18% Revenue & EBITDA CAGR over 3-4 years. FY27 capex similar to FY26's ~INR400cr. Atali Block 2 (INR149cr) commercialisation by H2FY28.
Risks
Elevated raw material costs from geopolitical tensions; Q2 margin down 265bps QoQ; FX and USD forward fair-value swings.
Investor Presentation filed with BSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹872.70
- Market cap
- ₹7,914 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 30.8×Sector 45.9×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Earnings Call Transcript: Key Takeaways
Aarti Pharmalabs delivered record quarterly revenue driven by strong CDMO growth, though aggressive capex is temporarily elevating debt and working capital.
- Call
- Guides 45% growth
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.